AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care? - Trefis

AI-generated analysis

📈 AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among U.S. companies.

💰 The company generated $18.21 billion in free cash flow over the trailing twelve months, fueling its robust capital return machine.

🚀 SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.

📊 AbbVie stock delivered a +161% total return over the past five years, significantly outperforming the S&P 500's +82% gain.

🎯 Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, supporting dividend commitments.

⚠️ The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive relative to growth.

🔬 Analysts probe risks regarding an increasingly crowded development landscape for AbbVie's key immunology drugs.

💼 Management recently announced a deal for Apogee Therapeutics to bolster its leading immunology portfolio.

Bullish Signals
  • AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among all U.S. companies.
  • The company generated $18.21 billion in free cash flow over the trailing twelve months, demonstrating a highly profitable business model.
  • SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.
  • Holding AbbVie stock produced a +161% total return over the past five years, nearly doubling the S&P 500's return.
  • Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, indicating strong commercial durability.
Risk Factors
  • The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive.
  • Analysts on the latest earnings call probed risks regarding an increasingly crowded development landscape for key drugs.
  • Investors face the risk that unexpected competitive inroads in immunology could quickly alter the company's cash return calculus.
Full Analysis
AbbVie (ABBV) has established itself as a major cash-return engine, returning approximately $62 billion to shareholders over the last five years through dividends and buybacks. This total represents about 13.4% of the company's current market value and ranks as the 25th largest among all U.S. companies. The substantial capital returns are fueled by a highly profitable immunology portfolio that has successfully replaced older revenue streams with a new generation of blockbuster drugs. The company's commercial durability is driven by SKYRIZI, which saw sales surge 24% to $5.5 billion in the most recent quarter, and RINVOQ, which climbed 24% to over $2.5 billion. These immunology products generated $18.21 billion in free cash flow over the last twelve months, supporting a history of potent shareholder returns including a +161% total stock return over five years, nearly double the S&P 500's performance. Management maintains confidence in its growth drivers, forecasting SKYRIZI to generate $21.7 billion in global revenues for the full year. However, investors are debating whether high cash returns come at the expense of reinvestment, noting a price-to-earnings multiple of 72.9 and potential risks from an increasingly crowded development landscape in immunology where competitive inroads could alter the company's calculus.